A double blind study on azathioprine efficacy in multiple sclerosis: final report
- PMID: 8326334
- DOI: 10.1007/BF00838165
A double blind study on azathioprine efficacy in multiple sclerosis: final report
Abstract
Forty patients, affected by multiple sclerosis with remitting-relapsing or progressive course, were included in a double blind study of treatment with azathioprine (2 mg/kg/day) lasting 3 years. The mean changes on the Expanded Disability Status Scale and in the survival analysis show a trend in favour of azathioprine both in slowing disease progression and reducing relapse frequency. These findings, repeatedly observed in similar trials, indicate that azathioprine should be used in the treatment of multiple sclerosis.
Similar articles
-
Double-masked trial of azathioprine in multiple sclerosis. British and Dutch Multiple Sclerosis Azathioprine Trial Group.Lancet. 1988 Jul 23;2(8604):179-83. Lancet. 1988. PMID: 2899660 Clinical Trial.
-
Cyclosporine versus azathioprine in the long-term treatment of multiple sclerosis--results of the German multicenter study.Ann Neurol. 1988 Jan;23(1):56-63. doi: 10.1002/ana.410230110. Ann Neurol. 1988. PMID: 3278672 Clinical Trial.
-
The efficacy of azathioprine in relapsing-remitting multiple sclerosis.Neurology. 1991 Jan;41(1):20-5. doi: 10.1212/wnl.41.1.20. Neurology. 1991. PMID: 1985289 Clinical Trial.
-
Mitoxantrone: a review of its use in multiple sclerosis.CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010. CNS Drugs. 2004. PMID: 15089110 Review.
-
Azathioprine and methotrexate in multiple sclerosis.J Neurol Sci. 2004 Aug 15;223(1):29-34. doi: 10.1016/j.jns.2004.04.016. J Neurol Sci. 2004. PMID: 15261557 Review.
Cited by
-
Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis.Cochrane Database Syst Rev. 2024 Sep 10;9(9):CD015443. doi: 10.1002/14651858.CD015443.pub2. Cochrane Database Syst Rev. 2024. PMID: 39254048 Free PMC article.
-
Disease Modifying Strategies in Multiple Sclerosis: New Rays of Hope to Combat Disability?Curr Neuropharmacol. 2024;22(8):1286-1326. doi: 10.2174/1570159X22666240124114126. Curr Neuropharmacol. 2024. PMID: 38275058 Free PMC article. Review.
-
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.Cochrane Database Syst Rev. 2024 Jan 4;1(1):CD011381. doi: 10.1002/14651858.CD011381.pub3. Cochrane Database Syst Rev. 2024. PMID: 38174776 Free PMC article. Review.
-
Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.Cochrane Database Syst Rev. 2023 Nov 30;11(11):CD012186. doi: 10.1002/14651858.CD012186.pub2. Cochrane Database Syst Rev. 2023. PMID: 38032059 Review.
-
Recent progress in epidemiology, clinical features, and therapy of multiple sclerosis in China.Ther Adv Neurol Disord. 2023 Sep 15;16:17562864231193816. doi: 10.1177/17562864231193816. eCollection 2023. Ther Adv Neurol Disord. 2023. PMID: 37719665 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical